MODD stock forecast, quote, news & analysis
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace... Show more
Why Modular Medical (MODD) Stock Is Down -57% in the Last 30 Days
Key Takeaways
- Modular Medical (MODD) closed at $1.87 on August 13, 2026, down approximately 57% from the $4.31 closing price recorded 30 calendar days earlier on July 14, 2026.
- The decline has pushed the stock toward the lower end of its 52-week range of $1.74–$30.00 and well below its 50-day moving average near $3.64.
- The sell-off followed a period of commercial-launch momentum, including FDA 510(k) clearance for the Pivot tubeless insulin patch pump in April 2026, that had lifted shares earlier in the year.
- Modular Medical remains essentially pre-revenue, with a trailing twelve-month net loss of about $28.2 million and roughly $6.9 million in cash as of its most recent quarter, keeping funding and dilution risk in focus.
- Heavy volume on August 13 and an increase in short interest to approximately 214,000 shares reflect fragile near-term sentiment.
Modular Medical (MODD) Company Overview and Market Position
Modular Medical, Inc. (NASDAQ: MODD) is a San Diego-based medical device company focused on insulin delivery technology. Its flagship product, the Pivot tubeless insulin patch pump, is designed for adults with type 1 and type 2 diabetes who use multiple daily injections. The company positions Pivot around simplicity and accessibility, targeting a large population of insulin users who have not adopted traditional pumps. After receiving FDA 510(k) clearance in April 2026, Modular Medical transitioned from a development-stage business into an early commercial-stage company, and investors now follow the stock primarily for launch execution, payer traction, manufacturing scale-up, and cash runway.
Modular Medical (MODD) Stock Price Performance: Last 30 Days vs. Quarter
Over the 30 calendar days ended August 13, 2026, MODD declined from a closing price of $4.31 on July 14 to $1.87, a drop of roughly 56.6%. The move was not a single-day event: the stock recorded sharp single-session declines on July 16 (-22.7%), July 24 (-17.4%), and August 13 (-9.7%), with the August 13 decline occurring on volume of about 1.6 million shares compared with an average closer to 129,000.
The weakness extends beyond the 30-day window. Over the trailing three months, MODD has fallen approximately 44.5% from a closing price of $3.37 on May 15. Year to date, the stock is down about 83% from $10.92 at the end of 2025, underscoring a sustained downtrend despite positive product-related milestones.
What Drove MODD Stock Price in the Last 30 Days
Early in the period, MODD benefited from a series of verified commercial updates, including the start of Pivot shipments to endocrinology practices, initial patient insulin deliveries, a pilot program with IMO Health to identify eligible patients through electronic health records, and the formation of a Pivot Innovation Council. Those announcements supported a late-June advance, with the stock trading as high as $5.81 intraday on June 26.
That optimism faded in mid-July as investors refocused on fundamentals. Modular Medical is still generating essentially no revenue while posting a trailing twelve-month net loss near $28.2 million. With about $6.9 million in cash as of its most recent quarter and negative operating cash flow, the company faces recurring questions about future capital raises and shareholder dilution. A $3.4 million registered direct offering priced at $4.50 per share in April 2026, along with earlier financing activity, kept those concerns in the foreground. The resulting selling pressure appeared amplified by risk-off sentiment in micro-cap healthcare names, with down days occurring on above-average volume and short interest rising from roughly 162,000 to about 214,000 shares.
What Drove MODD Stock Performance Over the Last Quarter
The broader three-month decline reflects a market repricing of an early commercial-stage medical device company that has achieved regulatory clearance but has yet to demonstrate revenue or a clear path to profitability. Positive developments included FDA clearance for Pivot, the first commercial shipments, manufacturing preparations, and new clinical-commercial partnerships. These were offset by ongoing cash burn, a 1-for-30 reverse stock split completed at the end of March 2026, a workforce reduction announced in March 2026 to lower operating expenses, and dilutive financing transactions. The result was a quarter in which improving commercialization news was outweighed by financing overhang, execution uncertainty, and weak sentiment toward pre-revenue small-cap medical technology stocks.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights a curated selection of AI-driven trading bots from a broader ecosystem of hundreds of bots that trade thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving traders a streamlined view of strategies that are currently attracting attention. The bots vary by trading style, timeframe, and performance metrics, so investors can compare approaches rather than relying on a single model. The page is designed to help users monitor which automated strategies are gaining traction in real market conditions. For those interested in exploring quantitative trading tools, the Trending AI Robots section offers a practical starting point.
MODD Stock Forecast Drivers: What Investors Should Watch Next
The most important factors for MODD going forward include the pace of Pivot commercial adoption, physician training, patient onboarding, and early repeat ordering. Reimbursement and payer coverage discussions will be critical, as will results from the IMO Health electronic health record pilot. Investors should also monitor the FDA’s response to the software enhancements the company has submitted for Pivot, along with any updates on manufacturing capacity and gross margin trajectory. The next quarterly earnings release and management commentary on cash runway will be closely watched, particularly for signals about future financing needs. Finally, Nasdaq listing compliance and the stock’s ability to hold above the $1.00 minimum bid threshold remain relevant risk factors amid a competitive insulin pump market.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsMODD's Stochastic Oscillator is staying in overbought zone for 3 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MODD declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
MODD broke above its upper Bollinger Band on August 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MODD entered a downward trend on August 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MODD's RSI Oscillator exited the oversold zone, of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on August 14, 2026. You may want to consider a long position or call options on MODD as a result. In of 104 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for MODD just turned positive on August 07, 2026. Looking at past instances where MODD's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .
MODD moved above its 50-day moving average on August 21, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MODD advanced for three days, in of 200 cases, the price rose further within the following month. The odds of a continued upward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.680) is normal, around the industry mean (11.035). P/E Ratio (0.000) is within average values for comparable stocks, (70.949). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.006). MODD has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (0.000) is also within normal values, averaging (34.463).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. MODD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MODD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices